Skip to main content
Samsung Biologics Co.,Ltd. (KRX:207940)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,593,000
+14,000 (0.89%)
Last updated: Mar 10, 2026, 12:02 PM KST

Samsung Biologics Revenue

In the year 2025, Samsung Biologics had annual revenue of 4.56T KRW with 30.31% growth. Samsung Biologics had revenue of 1.29T in the quarter ending December 31, 2025.

Revenue
4,556.97B
Revenue Growth
+30.31%
P/S Ratio
16.04
Revenue / Employee
955.34M
Employees
4,770
Market Cap
73.09T

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 20254,556.97B1,059.83B30.31%
Dec 31, 20243,497.15B-197.44B-5.34%
Dec 31, 20233,694.59B693.29B23.10%
Dec 31, 20223,001.30B1,433.29B91.41%
Dec 31, 20211,568.01B403.23B34.62%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Celltrion 3,895.99B
ALTEOGEN 202.18B
SK Biopharmaceuticals 675.41B
LigaChem Biosciences 159.27B
HLB Co., Ltd. 80.73B
Peptron 6.19B
Voronoi 7.49B
OliX Pharmaceuticals 10.18B
Revenue Rankings

Samsung Biologics News

More News